California’s Prop 61 Fails, But More Pricing Measures Could Be Ahead
Executive Summary
A combination of effective biopharma industry opposition as well as a poorly designed policy proposal probably doomed the drug pricing measure.
You may also be interested in...
Pharma Is Ready And Waiting For A Tax Holiday Under Trump
US biopharmas are holding billions in cash overseas to avoid paying America’s high corporate tax rate, so the prospect of a US tax holiday – or broad tax reform – will be welcomed by industry.
Trump’s ACA Repeal: What’s In It For Biopharma?
Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.
Trump’s ACA Repeal: What’s In It For Biopharma?
Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.